Trophoblast cell-surface antigen 2 (Trop-2) is highly expressed in non–small cell lung cancer (NSCLC) and has become an attractive target for antibody-drug conjugates (ADCs). Here, TACSTD2 is linked to non-small cell lung carcinoma.